Abstract
Elsewhere in this issue Sokal et al. report that the use of BCG in patients with lymphoma in remission prolongs the duration of remission. This observation must be interpreted in the frame of reference that knowledge of the pathogenesis, staging, prognostic factors and treatment of lymphoma is changing and advancing rapidly and that tumor immunology and immunotherapy is undergoing a similar evolution. Thus, clinical responsiveness is being interpreted in a group of patients randomly allocated to receive BCG between 1965 and 1967. Although randomization in this study was, in general, successful in terms of comparability, a tilt in the direction . . .
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
